Physician profile
Ashley Baker
NPI 1700343969
$814.68
in general payments reported to CMS, 2019-2025
13 companies · $53.85 in 2025
The $53.85 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $249 · 2022: $214 · 2023: $158 · 2024: $140 · 2025: $53.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $351.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $311.45 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $99.64 | 2022-2025 | Caplyta |
| Novo Nordisk INC | $93.15 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $50.28 | 2023 | Evusheld, Fasenra |
| Sunovion Pharmaceuticals INC. | $43.55 | 2021 | |
| Dexcom, INC. | $41.08 | 2022-2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $33.59 | 2023 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $29.28 | 2024 | |
| Glaxosmithkline, LLC. | $27.73 | 2023 | Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $26.94 | 2021-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Seqirus USA INC | $25.37 | 2025 | Flucelvax, Fluad |
| Medtronic, INC. | $19.07 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.